Valuation: Minerva Surgical, Inc.

Market Cap 10.39M 9.09M 8.38M 7.74M 14.69M 991M 14.93M 100M 39.32M 488M 39M 38.15M 1.68B P/E 2021
-1.68x
P/E 2022 -0.19x
Enterprise Value 43.14M 37.73M 34.8M 32.14M 60.99M 4.11B 62.02M 416M 163M 2.03B 162M 158M 6.97B EV / Sales 2021
2.82x
EV / Sales 2022 0.78x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
6.16
5 years 0
Extreme 0
207.4
10 years 0
Extreme 0
207.4
Manager TitleAgeSince
Chief Executive Officer 60 2024-08-18
Director of Finance/CFO - 2024-01-31
Chief Tech/Sci/R&D Officer 60 2010-12-31
Director TitleAgeSince
Chairman 58 2023-06-30
Director/Board Member - 2023-02-28
Date Insider Type Main position Quantity % Market Cap.
23-02-28
Accelmed Partners II Management, LLC
OtherCompany 122,189,638 83.3333%
23-02-08
Accelmed Partners II Management, LLC
OtherCompany 122,189,638 83.3333%
23-02-08
Accelmed Partners II Management, LLC
OtherCompany 122,189,638 83.3333%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8
+0.82%+0.99%-16.46%+11.68% 126B
+0.84%+1.15%-1.34%-2.61% 12.9B
-1.52%+2.95%+43.33%+115.86% 8.97B
+4.14%-2.38%-47.99%-72.05% 3.98B
-0.47%-1.34%+22.30%+45.04% 2.7B
+0.61%-7.70%-14.72%-20.20% 1.74B
+0.49%-3.87%-4.88%-25.01% 1.61B
+0.47%+10.24%-62.83%-83.35% 1.49B
Average +0.60%+0.13%-10.32%-3.83% 17.76B
Weighted average by Cap. +0.74%+1.01%-12.31%+13.25%

Financials

2021 2022
Net sales 52.1M 45.57M 42.04M 38.83M 73.67M 4.97B 74.91M 502M 197M 2.45B 196M 191M 8.42B 50.29M 43.99M 40.58M 37.48M 71.11M 4.8B 72.31M 485M 190M 2.36B 189M 185M 8.12B
Net income -21.46M -18.77M -17.32M -15.99M -30.35M -2.05B -30.86M -207M -81.25M -1.01B -80.59M -78.84M -3.47B -34.11M -29.84M -27.52M -25.42M -48.23M -3.25B -49.04M -329M -129M -1.6B -128M -125M -5.51B
Net Debt -1.33M -1.17M -1.08M -994K -1.89M -127M -1.92M -12.86M -5.05M -62.68M -5.01M -4.9M -215M 32.75M 28.64M 26.42M 24.4M 46.3M 3.12B 47.08M 316M 124M 1.54B 123M 120M 5.29B
Logo Minerva Surgical, Inc.
Minerva Surgical, Inc. is a medical technology company focused on advancing women’s health. The Company designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. It delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The Company's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. It also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.
Employees
174
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. UTRS Stock